Louisiana State Employees Retirement System Takes $3.12 Million Position in Medpace Holdings, Inc. $MEDP

Louisiana State Employees Retirement System purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,500 shares of the company’s stock, valued at approximately $3,121,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BOKF NA lifted its stake in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares during the last quarter. Valeo Financial Advisors LLC grew its position in shares of Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after acquiring an additional 24 shares during the period. Schulhoff & Co. Inc. lifted its position in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares during the last quarter. Finally, Kaufman Rossin Wealth LLC lifted its position in Medpace by 3.4% in the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays decreased their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Finally, Robert W. Baird lowered their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $467.08.

Medpace Price Performance

MEDP stock opened at $527.07 on Monday. The company has a 50-day simple moving average of $451.19 and a 200 day simple moving average of $496.65. The company has a market capitalization of $15.05 billion, a P/E ratio of 33.13, a PEG ratio of 2.67 and a beta of 1.18. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the company earned $3.67 EPS. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.